MYC oncogene is a transcription factor with a wide array of functions affecting cellular
activities such as cell cycle, apoptosis, DNA damage response, and hematopoiesis. Due to …

Stem cells are characterized by their ability to self-renew and differentiate into many different
cell types. Research has focused primarily on how these processes are regulated at a …

Marine-derived cyclic imine toxins, portimine A and portimine B, have attracted attention
because of their chemical structure and notable anti-cancer therapeutic potential …

A class of translation inhibitors, exemplified by the natural product rocaglamide A (RocA),
isolated from Aglaia genus plants, exhibits antitumor activity by clamping eukaryotic …

Pancreatic ductal adenocarcinoma (PDAC) is a lethal malignancy in need of new
therapeutic options. Using unbiased analyses of super-enhancers (SEs) as sentinels of core …

Multiple myeloma (MM) is a plasma cell tumor marked by clonal evolution and preceded by
a premalignant stage, which progresses via molecular pathway deregulation, including MYC …

Among cell death regulators, members of the Bcl-2 family are of interest because they are
highly conserved across species and represent promising targets for anticancer therapy …

Multiple Myeloma (MM) is an incurable disease characterized by a clonal evolution across
the course of the diseases and multiple lines of treatment. Among genomic drivers of the …

The translation inhibitor rocaglamide A (RocA) has shown promising antitumor activity
because it uniquely clamps eukaryotic initiation factor (eIF) 4A onto polypurine RNA for …

Abstract The PI3K/AKT/mTOR pathway is often activated in lymphoma through alterations in
PI3K, PTEN, and B-cell receptor signaling, leading to dysregulation of eIF4A (through its …